Beyond the Lab: Ethical, Legal and Social Implications in Health Biotechnology

Arsheen Tabassum*, *Mehvish* Fatima, *Safa* Fathima, *Shireen* Ameer, *Zainab* Fatima, *Nimrah* Fatima, *Pasupuleti* Angelina, *Anushka* Battula

St. Francis College for Women, Begumpet, Hyderabad, Telangana, India.

Abstract. Artificial intelligence (AI) is driving major changes in Healthcare, by improving the accuracy of diagnostics and enabling more personalised and effective treatments, moreover, enhancing the way of delivering the healthcare services. In the year 2024 the global demand for AI in Healthcare reached about 29.01 billion USD, with the projections estimated to rise to around 504.17 billion USD by the year 2032, which reflects a compound annual growth rate (CAGR) of 44%. While incorporating the AI with biotechnology, it raises many complex 'ethical' 'legal' as well as 'social issues' which includes patient autonomy, statistical bias, privacy concerns, and reliance on the animal studies. This paper critically examines and talks about the implications in health biotechnology and considers how ethical standards and legal framework along with social pressures shapes the responsible use of the AI in the field of medicine. The analysis highlights the need for the ethical oversight and clarifies legal guidelines, and unbiased access in AI-based biomedical revolution. The guidelines help us to ensure that AI develops in a responsible, fair and scientific sound way.

Keywords. Artificial Intelligence, Biotechnology Advancements, Ethical, Legal Issues and Social Implications.

*Corresponding author: arsheen.tabasum@sfc.ac.in

1 Introduction

Currently, the regulation of AI-powered medical assessments is experiencing a rapid transformation and a significant global disorder. This kind of situation happens because, of the absence of a single, globally adopted framework [1]. Although most of the initial tools come under the category of Software as a Medical Device (SaMD), the critical regulatory challenge lies with the Self-learning Algorithms (SiMD) systems that constantly learn and adapt after the deployment. Traditionally fixed approval models are fundamentally not equipped to manage the software that is never truly static [2]. In response, to the US Food and Drug Administration (FDA) had founded the Total Product Lifecycle (TPL) approach. This approach shifts the scrutiny to the manufacturer's quality and development processes. This approach facilitates the controlled updates through a predetermined Change Control Plan (PCCP), thereby optimising the safe iteration process. [2] In contrast, the 'European Union' must navigate a complex dual system governed by the 'Medical Device Regulation' (MDR) and the 'European Union's Artificial Intelligence Act' (EU AI Act). These regulations categorise most of the medical AI as "high-risk," there by imposing the requirements for the data governance, quality management, and the mandatory bias mitigation. [3] Core regulatory efforts globally are focused on ensuring the transparency, promoting fairness (requiring a sturdy approval with balanced data to eliminate systemic bias), and a clarifying liability (determining the responsibility between the developer and the healthcare provider when the errors occur). This necessity pushes the regulatory framework away from the simple product approval towards the governance of a dynamic, evolving service that requires continuous monitoring and a strict post-market surveillance.

This study adopts a narrative review approach to explore the 'ethical', 'legal' and 'social implications' of 'artificial intelligence' (AI) in biotechnology and healthcare. Literature searches across 'PubMed', 'Medscape', and the 'Google Scholar' focusing on the publications from 2021-2024. Inclusion criteria encompassed the peer-reviewed 'journal articles', 'conference papers', 'policy reports', and the authoritative institutional publications that addressed ethical, legal and social concerns related to AI in the sector of biotechnology. Approximately 25 scholarly sources were screened, of which few were selected based on the relevance and its quality, forming the evidence base for this analysis and the proposed framework.

2 Ethical Issues in AI-Driven Biotechnology

2.1 Biomedical Ethics Principles and AI Implementation

AI applications in healthcare must adhere to the four foundational principles they are: 'autonomy', 'beneficence', 'non- maleficence' and 'justice'. An emerging concept of "explainability" calls for the AI systems that should be understood by the humans which makes the comprehension between the patient and the clinicians easier**.** [4] However, the complexity and limited understanding of the machine learning models pose a significant challenge in the clinical applications. Patients often lack comprehension of algorithmic recommendations, deteriorating an informed consent and the patient autonomy. The authority of decision-making is given to the systems, the recommendations of which may not be entirely comprehensible or justifiable, it can question clinician accountability. Consequently,

instances of error or the inaccurate recommendations may lead to the uncertainty regarding the resultant outcomes. [5].

2.2 Algorithmic Fairness and Systemic Bias

Algorithmic bias in AI systems can intensify the pre-existing healthcare inequalities. Such bias in the field of medical Artificial Intelligence (AI) can arise and assemble across the entire AI lifecycle, from data collection and annotation to the model development, assessment, positioning, and even issuing. For example, the insufficient sample sizes for a certain group of patients can result in suboptimal performance, and clinically unmeaningful predictions. [6]

AI models which are trained on a specific patient populations perform poorly when applied to different groups due to changes in the demographic or the clinical characteristics. This limited validity results in the less accurate recommendations in the real-world settings, as there is a lack of representation among the AI developers. For example, an AI model developed for the cardiovascular prediction using a predominantly male patient data may not work accurately for women. Algorithms rely on "big data," such as medical records, imaging and biomarker values, but they still fail to incorporate "small data," such as social determinants of the health which include factors like transit access, availability of the healthy food, and patient's community and the work schedules [6]

2.3 Alternatives to Traditional Animal Testing

Historically, biotechnology has extensively utilized the animal testing method for the production of drugs and the evaluation of the toxicity. Growing regulatory demands, exemplified by the 'European Union's' "3Rs" initiative aiming to 'replace', 'reduce', and 'refine' animal experimentation, highlighting the movement towards the non-animal methodologies [7]. According to a 2020 estimate by the 'European Union' approximately '8 million' animals, were used for the scientific purposes.

An advanced approach uses live human cells to build 'organ-on-chip' models that mimic the tissues of the organs such as the lung, liver, and gut. A study published in 'Nature Reviews Genetics' by Donald E. Ingber in 2022 shows how lung-on-chip technologies have successfully replicated the complicated physiological reactions like inflammation, fluid buildup (edema), and the infection. This advancement allows for the evaluation of drug toxicity and its effectiveness in a manner that more accurately reflects human bodily functions compared to the traditional animal testing methods. As a result, these organ-on-chip platforms are being considered as the alternatives for certain animal tests in toxicity evaluations which supports the 3Rs framework by offering the more reliable predictions of human responses [8].



Fig. 1. Gene editing, regulatory supervision, data privacy, cloning, and environmental hazards are also some of the ethical issues in biotechnology

3 Legal Implications

3.1 Regulatory Frameworks

Global frameworks governing the artificial intelligence in healthcare presents a diverse range of scope and rigor. The United States follows a regulatory framework, primarily through the Food and Drug Administration, the software embedded in the Medical Device oversees the complete product lifecycle. This methodology is largely sufficient for algorithms that do not undergo modifications after deployment, but it encounters difficulties with the adaptive systems that can evolve after its initial launch. In contrast, European and the other legislative bodies have established the AI-specific regulations that classify a significant portion of clinical AI tools as high-risk. These regulatory requirements impose the need for a systematic approach for the risk management, documentation and human supervision, thereby, indicating a more cautious strategy for the implementation of the medical AI. [9]

3.2 Responsibility and Liability

Identifying the legal responsibility when AI plays a role in the medical harm is complicated, as most of the legal frameworks are adapting established principles instead of forming the entirely new ones. Evaluations of European initiatives regarding the AI liability and U.S. practices indicate that the damages could be pursued under the ‘product-liability’ claims against the manufacturers, negligence-related malpractices against healthcare providers or the institutions, or a mix of both, depending on the integration of AI in treatment. Researchers say that clinicians, institutions and developers each have a specific role to validate and oversight for the secure implementation of ‘clinical AI’ [9].

3.3 Cross-Border Data and Clinical AI

Creating clinical AI models usually requires large datasets collected from the various locations. Regulation's concerning the privacy and data safeguarding present significant, obstacles to the ‘international exchange of health information’. bulibdeh and his colleagues point out that even within a single regulatory body like the FDA, information regarding training datasets, validation groups, and the appropriateness of the models for varied demographic groups is frequently insufficient. This deficiency makes it difficult to assess safety when these tools are employed in settings distinct from their original development [10]. Therefore, Panch and his collaborators argue that strong governance structures should include not only the broad regulations on data privacy and permissions but also site-specific management systems. These local systems would be tasked with managing constraints on data transfer, monitoring the performance in practical use, and ensuring equity across different settings. [9]



Fig. 2. Highlights important biotechnology-related legal concerns, such as ownership, liability, bioterrorism, and AI regulations.

4 Societal Impacts

4.1 Public Trust

Trust is paramount for AI's role in the healthcare. ‘Transparency’, ‘accountability’, and ‘physician involvement’ all these greatly improve the public acceptance. The ‘Pew Global Attitudes’ survey in 2021 discovered that the nations with robust regulatory frameworks (like those in European Union) had the highest levels of trust. As a result this strongly implies the public’s acceptance and adoption of AI technology in healthcare are heavily influenced by legislation highlighting the critical role of effective regulatory

frameworks in building trust. Which ensures the responsible implementation of the data. [11]

4.2 Equity and Access

AI has the ability to expand the access to the healthcare, but it can also make the existing inequalities worse. Many rural areas in the country still lack the reliable internet, proper electricity, and also the trained medical staff needed who is experienced to use the AI-based tools effectively. According to the 'World Health Organization' (WHO, 2021), 47% of the low-income countries do not have the digital substructure needed for the healthcare in AI. [10]

This reality was obvious from the case study 'India's rural TB screening efforts' in 2021, where the AI-assisted chest X-ray systems showed improved observation accuracy but could not be implemented due to the poor internet connectivity in the health centres and clinics. This highlights how the infrastructural limitations continue to act on major drawback to the fair and widespread use of the AI in healthcare biotechnology. [12]

4.3 International and Cultural Challenges

AI systems are primarily trained on the data gathered from the 'high income nations', which results in inaccurate performance. In low resource settings, this disparity can lead to a problem called as 'Data Colonialism'. This results in tools which do not reflect localised languages, values, or healthcare needs, which makes them less effective and less harmful. Cultural lack of the reactivity limits acceptance, as shown by a case in 2023 which involves a 'government-sponsored mental health Chatbot', which was criticised for giving advice that did not align with the cultural expectations from the people.

Public backlash in the society eventually led to the shutdown of the Chatbot, clearly showing that for the AI to succeed globally, it must be designed with cultural awareness, local and societal contexts in the mind [13].



Fig. 3. Social issues in biotechnology include equal access, professional responsibilities, job loss, and public trust.

5 Conceptual Framework for Responsible AI Biotech

An inclusive framework with the ethical, legal, and societal safeguards for the entire AI biotechnology life cycle is needed to overcome the failings of the incompetent policy directives. This framework consists of a six-phase model able to serve as a governance road map in 'manifold contexts'. To validate the relevance and the applicability of their goals, there needs to be a stakeholder engagement as in the first stage, entailing the collaboration of clinicians, patients, agencies, and the developers themselves. In step two: value alignment, there is a need for integrating the 'across-the-board' quantitative design requirements in the form of ethical principles like 'autonomy', 'beneficence', and 'justice' to make sure that the AI systems follow accepted biological and the ethical norms. The third step: ethical modelling, provides a detailed list of the documentation, fairness assessments, measures for data openness, and the accuracy assessments. The fourth level: transparency in application, says there is a need to provide clinicians with clear results, along with protection mechanisms and ambiguity detectors to facilitate the appropriate decisions. Step five: regulatory conformance, requires platforms to adhere to the local laws, thus complying with international safety standards, such as the EU AI Act, 2024, or the FDA's SaMD Action Plan, 2021. Continuous monitoring, the final phase, indicates that the post-deployment auditing is needed, along with rollbacks and change of the drift detection, with respect to the adaptively governing and the ongoing technological evolution. It will be repetitive and cyclical in nature, standing upon a continuous improvement process through feedback loops so that updates in the human values, societal requirements, and developments along with that the AI-biotechnology front are kept aligned.

6 Future Directions

As the research study in biotechnology moves from the lab to digitally connected healthcare and the research system. Its ethical, legal, and social implications have become very important for the responsible innovation.The increasing use of 'Artificial intelligence'[AI], 'Genomics' and the high-performance, computing has increased the concern's regarding 'data privacy' 'informed concerned' 'algorithmic transparency' and accountability. While the federated and the privacy-preserving learning systems reduce the need to share raw patient data, the future governance still have the need to address issues like bias, data leakage, and the cross-border data control. The International regulatory coordination like the development of quantum-resistant data security systems, and the direct integration of ethical assessment into technological design are the significant measures of the future directions

The national policies differ from one country to the another, Global co-operation through the organizations like 'UNESCO, WHO, and OECD' play a crucial role. This cooperation helps to prevent the fragmented innovation and promotes a safe and fair progress in the sector of biotechnology. The biotechnology workforce is rapidly evolving due to the growing influence of Artificial Intelligence. All these changes show that the future of biotechnology relies on Collaboration, Flexibility, and Regulations that work together globally. This kind of approach ensures that the scientific progress, remains connected to 'Social Responsibility'.

7 Conclusion

By improvising the effectiveness in the field of 'Diagnosis', 'Treatment', and 'Research'. Artificial Intelligence can revolutionize biotechnology and healthcare. But it also brings up the important legal, ethical, and the social issues like 'algorithmic bias', 'data privacy', 'accountability', 'unequal access', and 'workforce shifts'. This study explains the necessity of the open AI systems, robust and adaptable regulation's, ongoing oversight, and the equitable access to the technology. AI could be applied safely and effectively in biotechnology in the future by striking a balance between the innovation, ethics, equity, and social responsibility.

References

1. Carolan, J. E., McGonigle, J., Dennis, A., Lorgelly, P., & Banerjee, A. (2022). Technology-Enabled, Evidence-Driven, and Patient-Centered: The Way Forward for Regulating Software as a Medical Device. *JMIR Medical Informatics, 10*(1), e34038.(2022) https://doi.org/10.2196/34038

2. Hopkins D, Arbuckle L, Long J, et al. A general framework for governing marketed AI/ML medical devices. (2024)https://pubmed.ncbi.nlm.nih.gov/40450160/

3. Harwich, T., & Pollock, A. (2025). How AI challenges the medical device regulation: Patient safety, benefits, and intended uses. Journal of Law and the Biosciences.

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4638548

4. Gorelik, A. J., Li, M., Hahne, J., Wang, J., Ren, Y., Yang, L., Zhang, X., Liu, X., Wang, X., Bogdan, R., & Carpenter, B. D. (2025). *Ethics of AI in healthcare: A scoping review demonstrating applicability of a foundational framework*. Frontiers in Digital Health, 7, 1662642. https://doi.org/10.3389/fdgth.2025.1662642

5. Weiner, E. B., Dankwa-Mullan, I., Nelson, W. A., & Hassanpour, S. (2025). Ethical challenges and evolving strategies in the integration of artificial intelligence into clinical practice. *PLOS Digital Health, 4*(4), e0000810. https://doi.org/10.1371/journal.pdig.0000810

6. Cross, J. L., Choma, M. A., & Onofrey, J. A. (2024). Bias in medical AI: Implications for clinical decision-making. *PLOS Digital Health*, *3*(11), Article e0000651. https://pmc.ncbi.nlm.nih.gov/articles/PMC11542778/

7. Schmerbeck, S., Schulze, F., Scheinpflug, J., & Ebrahimi, L. (2021). Organ-on-chip systems and the 3Rs. *Science in School*, *54*. https://scienceinschool.org/article/2021/organ-on-chip/

8. Ingber, D. E. (2022). Human organs-on-chips for disease modelling, drug development and personalized medicine. *Nature Reviews Genetics*, *23*(8), 467–491. https://www.nature.com/articles/s41576-022-00466-9
9. Panch, T., Duralde, E., Mattie, H., Kotecha, G., Celi, L. A., Wright, M., & Greaves, F. (2022). A distributed approach to the regulation of clinical AI. *PLOS Digital Health, 1*(5), e0000040. https://doi.org/10.1371/journal.pdig.0000040

10. Abulibdeh R, Celi LA, Sejdić E (2025). The illusion of safety: A report to the FDA on AI healthcare product approvals. *PLOS Digital Health*. https://doi.org/10.1371/journal.pdig.0000866

11. Poushter, J., Fagan, M., & Corichi, M. (2025, October 15). *How people around the world view AI*. Pew Research Center. https://www.pewresearch.org/global/2025/10/15/how-people-around-the-world-view-ai/

12. International Telecommunication Union. (2021, November). *Facts and figures 2021: 2.9 billion people still offline*. https://www.itu.int/hub/2021/11/facts-and-figures-2021-2-9-billion-people-still-offline/

13. Joseph, J. (2025). Algorithmic bias in public health AI: A silent threat to equity in ... *[Article]*. *PMC*. https://pmc.ncbi.nlm.nih.gov/articles/PMC12325396/